{
    "nctId": "NCT00241449",
    "briefTitle": "A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer",
    "officialTitle": "A Double-blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Metastasis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 51,
    "primaryOutcomeMeasure": "Time to disease progression (TTP)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Biopsy confirmation of breast cancer. Evidence of breast cancer that is not considered amenable to curative treatment.\n\nPostmenopausal women. Written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Previous treatment with hormonal therapy unless that therapy was tamoxifen for adjuvant breast cancer. The use of tamoxifen must have ceased at least one year before this study.\n\nPrevious treatment with Faslodex. Any existing serious disease, illness, or condition that will prevent participation or compliance with the study procedures.\n\nTreatment with an investigational or non-approved drug within one month of then start of the study.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}